We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
VECT

Price
-
Stock movement up
+- (%)
Company name
VectivBio Holding AG
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Pharmaceuticals
Market cap
1.06B
Ent value
876.10M
Price/Sales
1565.50
Price/Book
4.96
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
180.37%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2024-12-17

DIVIDENDS

VECT does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF80.46
Price to FCF40.34
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales1565.50
Price to Book4.96
EV to Sales1296.00

FINANCIALS

Per share

Loading...
Per share data
Current share count62.81M
EPS (TTM)-1.63
FCF per share (TTM)0.59

Income statement

Loading...
Income statement data
Revenue (TTM)676.00K
Gross profit (TTM)676.00K
Operating income (TTM)-71.96M
Net income (TTM)-71.98M
EPS (TTM)-1.63
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-10644.90%
Profit margin (TTM)-10648.34%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash221.42M
Net receivables1.43M
Total current assets226.21M
Goodwill923.00K
Intangible assets25.23M
Property, plant and equipment0.00
Total assets252.60M
Accounts payable1.80M
Short/Current long term debt10.46M
Total current liabilities24.74M
Total liabilities39.23M
Shareholder's equity213.37M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)13.15M
Capital expenditures (TTM)79.75K
Free cash flow (TTM)26.23M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-33.74%
Return on Assets-28.50%
Return on Invested Capital-33.71%
Cash Return on Invested Capital12.29%

STOCK INFORMATION

Downside potential

Loading...
Downside potential data
VECTS&P500
Current price drop from All-time high-30.46%-4.92%
Highest price drop-88.32%-56.47%
Date of highest drop3 Dec 20219 Mar 2009
Avg drop from high-65.60%-11.07%
Avg time to new high573 days12 days
Max time to new high572 days1805 days
COMPANY DETAILS
VECT (VectivBio Holding AG) company logo
Marketcap
1.06B
Marketcap category
Small-cap
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
Employees
0
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner